Precision medicine and Ōmics-based health management provides an unprecedented opportunity to improve policyholder engagement, persistence, and mortality rates. We can reduce your pipeline development costs and dramatically increase your ability to launch new and innovative products.
Reinforce your brand’s commitment to innovation and value
cancerŌme™ is the world’s first co-branded omics-based insurance product designed to be added as a rider to an existing critical illness or life policy, or as a new stand-alone disease-specific policy.
So much more than financial coverage
Our products are sold by insurance companies as a rider to an existing critical illness or life policy, or as a new stand-alone disease-specific policy. As well as the standard financial protection included in these types of policies, a healthŌme™ powered policy also includes:
Disease risk management
Proactive genetic screening & ongoing risk stratification, genetic counseling and action plan.
Active disease management
Molecular Diagnostic & Precision Treatment Recommendation Report, 1:1 Nurse-Led Advocacy, Health System Navigation, Clinical Trial Evaluation and Enrollment and Expert Reviews.
Disease recovery and monitoring
Molecular Residual Disease (MRD) monitoring and support to detect disease early so it’s easier to treat.
The old carrier product development experience
✗ Limited product differentiation options
✗ Huge barriers to entry in the genomics and precision medicine product space
✗ Limited and slow product innovation
✗ No influence on health outcomes
✗ Difficult to gain new customers or enter new markets
The cancerŌme™ powered product development experience
✓ Turnkey genomics-based product offering
✓ High value-add product & service features
✓ Strong differentiating characteristics
✓ Rapid [low-risk] product innovation
✓ Potential to improve health outcomes and mortality
✓ Simplified access to new markets and new customers